BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang YY, Deng J, Tian YJ, Liang J, Xie X, Huang Y, Zhu J, Zhu Z, Zhou Q, He X, Luo HB. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety. J Med Chem 2021;64:13736-51. [PMID: 34520193 DOI: 10.1021/acs.jmedchem.1c01085] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Su X, Tan Z, Wang G, Liu Z, Gan C, Yue L, Liu H, Xie Y, Yao Y, Ye T. Design, synthesis and biological evaluation of novel diarylacylhydrazones derivatives for the efficient treatment of idiopathic pulmonary fibrosis. European Journal of Medicinal Chemistry 2022. [DOI: 10.1016/j.ejmech.2022.114918] [Reference Citation Analysis]
2 Liu H, Wang Q, Huang Y, Deng J, Xie X, Zhu J, Yuan Y, He YM, Huang YY, Luo HB, He X. Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases. Eur J Med Chem 2022;242:114631. [PMID: 35985255 DOI: 10.1016/j.ejmech.2022.114631] [Reference Citation Analysis]
3 Li J, Wang Y, Wang R, Wu MY, Shan J, Zhang YC, Xu HM. Study on the molecular mechanisms of tetrandrine against pulmonary fibrosis based on network pharmacology, molecular docking and experimental verification. Heliyon 2022;8:e10201. [PMID: 36046534 DOI: 10.1016/j.heliyon.2022.e10201] [Reference Citation Analysis]
4 Takeuchi T, Hayashi M, Tamita T, Nomura Y, Kojima N, Mitani A, Takeda T, Hitaka K, Kato Y, Kamitani M, Mima M, Toki H, Ohkubo M, Nozoe A, Kakinuma H. Discovery of Aryloxyphenyl-Heptapeptide Hybrids as Potent and Selective Matrix Metalloproteinase-2 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis. J Med Chem 2022;65:8493-510. [PMID: 35687819 DOI: 10.1021/acs.jmedchem.2c00613] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Huang MX, Tian YJ, Han C, Liu RD, Xie X, Yuan Y, Yang YY, Li Z, Chen J, Luo HB, Wu Y. Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects. J Med Chem 2022. [PMID: 35666471 DOI: 10.1021/acs.jmedchem.2c00458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Song Z, Huang YY, Hou KQ, Liu L, Zhou F, Huang Y, Wan G, Luo HB, Xiong XF. Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis. J Med Chem 2022. [PMID: 35188767 DOI: 10.1021/acs.jmedchem.1c02058] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]